alpha-Glucosidase inhibitory activity and cytotoxic effects of some cyclic urea and carbamate derivatives
AutoriPopovic-Djordjevic, Jelena B.
Jevtic, Ivana I.
Grozdanic, Nadja Dj
Šegan, Sandra B.
Članak u časopisu (Objavljena verzija)
MetapodaciPrikaz svih podataka o dokumentu
The inhibitory activities of selected cyclic urea and carbamate derivatives (1-13) toward alpha-glucosidase (alpha-Gls) in in vitro assay were examined in this study. All examined compounds showed higher inhibitory activity (IC50) against alpha-Gls compared to standard antidiabetic drug acarbose. The most potent was benzyl (3,4,5-trimethoxyphenyl) carbamate (12) with IC50 = 49.85 +/- 0.10 mu M. In vitro cytotoxicity of the investigated compounds was tested on three human cancer cell lines HeLa, A549 and MDA-MB-453 using MTT assay. The best antitumour activity was achieved with compound 2 (trans-5-phenethyl-1-phenylhexahydro-1H-imidazo[4,5-c] pyridin-2(3H)-one) against MDA-MB-453 human breast cancer cell line (IC50 = 83.41 +/- 1.60 mu M). Cyclic ureas and carbamates showed promising anti-alpha-glucosidase activity and should be further tested as potential antidiabetic drugs. The PLS model of preliminary QSAR study indicated that, in planing the future synthesis of more potent compounds,... the newly designed should have the substituents capable of polar interactions with receptor sites in various positions, while avoiding the increase of their lipophilicity.
Ključne reči:alpha-Glucosidase inhibitors / carbamates / cyclic ureas / cytotoxicity / QSAR
Izvor:Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 1, 298-303
- Taylor & Francis Ltd, Abingdon
- Sinteza aminohinolina i njihovih derivata kao antimalarika i inhibitora botulinum neurotoksina A (RS-172008)
- Proučavanje odnosa strukture i aktivnosti novosintetisanih biološki aktivnih supstanci (RS-172032)
- Interakcije prirodnih proizvoda, njihovih derivata i kompleksnih jedinjenja sa proteinima i nukleinskim kiselinama (RS-172055)
- Modifikatori biološkog odgovora u fiziološkim i patološkim stanjima (RS-175011)